ライフサイエンスコーパス: stable disease

1 21.7%) met PFS3 (two partial response, three stable disease).

2 n five patients (two partial response, three stable disease).

3 70 (38%) had stable disease.

4 sponse, 11 had partial responses, and 66 had stable disease.

5 d CR for almost 2 years, and 3 had transient stable disease.

6 though four (80%) of those patients achieved stable disease.

7 d response criteria), and three instances of stable disease.

8 died during chemotherapy, and all others had stable disease.

9 SCT had disease progression, while 11 showed stable disease.

10 sponse and 73 (42%) of 172 women with RECIST stable disease.

11 phocytosis; the remaining 5% of patients had stable disease.

12 riteria for renal response and six (40%) had stable disease.

13 teria for cardiac response and six (43%) had stable disease.

14 R2 or FGFR3 translocations); 16 patients had stable disease.

15 osis; the remaining three (20%) patients had stable disease.

16 trocytoma with clinically and radiologically stable disease.

17 n one or more HRQOL scales despite long-term stable disease.

18 (8.1-20.1; 171 events) for those with RECIST stable disease.

19 response; the remaining 3 patients (13%) had stable disease.

20 rs had a partial response and 7 patients had stable disease.

21 wo showed partial response, and 13 exhibited stable disease.

22 had dexamethasone added, 4 achieved at least stable disease.

23 four achieved partial response, and four had stable disease.

24 had a partial response, and 10 patients had stable disease.

25 e patient had a partial response and ten had stable disease.

26 Eleven (52%) of 21 patients experienced stable disease.

27 rable for patients with tumor regression and stable disease.

28 34 (65%) patients had stable disease.

29 ents with WDLS or DDLS experienced prolonged stable disease.

30 ma response criteria, 9 patients (26.5%) had stable disease.

31 l response rate was 41%; 39% of patients had stable disease.

32 al 12 patients (52%, 95% CI 31-73) achieving stable disease.

33 r antibiotic treatment and during periods of stable disease.

34 achieved partial responses and 12 (54%) had stable disease.

35 ents included those with cachexia and weight-stable disease.

36 .0% to 40.4%) were observed; 12 patients had stable disease.

37 6 of these 8 patients had more than 6 mo of stable disease.

38 An additional 21% of patients had stable disease.

39 espectively) and 5 patients (31.3%) achieved stable disease.

40 41% (7/17); 6 additional patients (35%) had stable disease.

41 rtial response, and three patients (13%) had stable disease.

42 0% (95% CI 6.8-40.7), and 13 (52%) of 25 had stable disease.

43 3 patients; 30 (57%) additional patients had stable disease.

44 te remission, 3.92% partial remission, 1.96% stable disease, 1.96% disease-related death, and 1.96% a

45 disease, had a partial response or prolonged stable disease (10, >/= 6, and >/= 7 months).

46 t response at 4 months (modified RECIST) was stable disease: 12 of 23 (52%) in the ADI-PEG20 group vs

47 dence interval [CI], 178-303 Gy; n = 32) and stable disease (147 Gy; 95% CI, 113-191 Gy; n = 28) (P =

48 uated patients, 35 had partial remission, 16 stable disease, 15 mixed response, and 36 progression of

49 sions, 25 partial responses, 18 responses of stable disease, 2 unevaluable responses.

50 p, 55.3% were in disease remission, 5.0% had stable disease, 28.1% were deceased, and 11.7% were on a

51 as complete or partial response, 17 cases as stable disease, 5 cases as progressive disease, and 14 c

52 l remission (11.5%) and 13 patients achieved stable disease (50%), with an overall disease control ra

53 lete response, 31%) and 20 nonresponders (13 stable disease, 7 progressive disease, 69%).

54 ng a complete response, partial response, or stable disease according to local Response Evaluation Cr

55 achieved a partial response and 14 (50%) had stable disease according to Response Evaluation Criteria

56 s had a partial response and one patient had stable disease according to surface measurements derived

57 often continued during pregnancy to maintain stable disease activity.

58 d as complete response, partial response, or stable disease after 12 weeks, assessed with modified WH

59 Patients who achieved at least stable disease after 4 treatments could receive another

60 If there is stable disease after 6 months of induction chemotherapy

61 For patients who achieved CR/PR or stable disease after cycle 1, one year overall survival

62 Patients with responsive or stable disease after induction treatment, with adequate

63 , 55 patients with inoperable mCRC and prior stable disease after standard chemotherapy were enrolled

64 Patients with responsive or stable disease after the first stage were then randomly

65 Stable disease after treatment (hazard ratio, 0.017 vs.

66 5 had confirmed partial responses and 3 had stable disease; all patients had decreases in serum thyr

67 ) (all partial response), with 26% (4 of 15) stable disease and 20% (2 of 15) progressive disease.

68 of 17] partial response), with 18% (3 of 17) stable disease and 30% (5 of 17) progressive disease.

69 n, 33 mo; interquartile range, 20-48 mo) had stable disease and 32 (74.4%; median, 19 mo; interquarti

70 ents with a complete or partial response (or stable disease and clinical benefit) continued to receiv

71 st, pathogen, and resident microbiota during stable disease and exacerbations.

72 rculation of patients with COPD, during both stable disease and exacerbations.

73 In addition, 18 (50%) patients achieved stable disease and none showed progression while on ther

74 N = 29), including nine patients (31%) with stable disease and one patient (3.4%) with partial respo

75 rs were compared with those of patients with stable disease and progressive disease.

76 (one unconfirmed); eight (38%) patients had stable disease and the remaining two (10%) had progressi

77 e, partial response, progressive disease, or stable disease) and in the differentiation between progr

78 py (complete response vs partial response vs stable disease) and primary refractory Hodgkin's lymphom

79 RECIST was 2 with partial response, 36 with stable disease, and 1 with progressive disease (n = 39).

80 as 2.6 months for all tumors, 1.5 months for stable disease, and 1.3 months for progressive disease.

81 artial response, 17.6% minor response, 35.1% stable disease, and 10.8% progressive disease for the en

82 artial response, 17.1% minor response, 48.8% stable disease, and 12.2% progressive disease for nonpan

83 3 mo, 5 patients showed partial response, 26 stable disease, and 17 progressive disease.

84 e considered to have responded, 19 (21%) had stable disease, and 19 (21%) developed diseases progress

85 9 (53%) had a partial response, 3 (18%) had stable disease, and 2 (12%) had progressive disease at t

86 = 3) response, 1 had a mixed response, 4 had stable disease, and 6 had progressive disease.

87 nalysis, 3 patients had partial response, 49 stable disease, and 6 progressive disease after 6 wk.

88 (27%) had a partial remission, 55 (42%) had stable disease, and 8 patients (6%) had progressive dise

89 artial response, 18.2% minor response, 18.2% stable disease, and 9.1% progressive disease for pancrea

90 esponse (at 250, 400, and 500 mg), 31 showed stable disease, and eight had progressive disease.

91 Twelve patients (21%) had stable disease, and five patients (9%) had primary refra

92 CI 5-29) achieved a partial response, 28 had stable disease, and four had progressive disease.

93 and nine partial responses; 14 patients had stable disease, and nine progressed.

94 with disease progression, two patients with stable disease, and objective response in 24 patients, i

95 ponse rate, 65%; 95% CI, 49% to 81%); 11 had stable disease, and one had progressive disease.

96 cal response to the treatment, with at least stable disease, and only 1 had to stop the therapy after

97 sponse [+minor response for mRECIST/mSWOG]), stable disease, and progressive disease (PD) were 28%, 4

98 Complete and partial response, stable disease, and progressive disease were defined acc

99 iteria are provided for progressive disease, stable disease, and relapse.

100 th progressive disease than in patients with stable disease, and rising concentrations of CA-125 over

101 3%) achieved partial response, six (20%) had stable disease, and seven (23.3%) exhibited KS progressi

102 5% CI 0-26) had a partial response, five had stable disease, and seven had progressive disease.

103 ad a partial response, 14 (67%) patients had stable disease, and six (29%) patients had progressive d

104 a partial response, 12 (75%, 47.6-92.7) had stable disease, and three (19%, 4.1-45.7) had progressiv

105 0 (40%) had a partial response, 13 (52%) had stable disease, and two (8%) had nonevaluable disease.

106 sponses, 15 (65%, 95% CI 42.7-83.6) achieved stable disease, and two (9%, 1.1-28.0) had progressive d

107 508del mutation, aged 12 years or older with stable disease, and with a percentage predicted forced e

108 Three patients with stable disease are alive without any evidence of progres

109 onse > 36 months; 24 patients (56%) achieved stable disease as best confirmed response.

110 study, was defined as progressive disease or stable disease as best response at any point during chem

111 Complete response, partial response, and stable disease as best response were achieved by 2%, 12%

112 An additional 15 patients had RECISTv1.1 stable disease as best response.

113 disease, 59 (92%) had a partial response or stable disease as the best objective response within 12

114 spanning > 2 years, whereas 42 patients had stable disease as the best overall response.

115 Twenty-six patients (60%) had stable disease as the best response, with a disease cont

116 se control (they had a confirmed response or stable disease as their best overall response).

117 Another five patients with prolonged stable disease as their best response remain on study.

118 All 10 patients who continued treatment had stable disease at 3 mo.

119 ients with a complete or partial response or stable disease at 6 months.

120 Five of 10 evaluable patients had stable disease at 8 wk, and 1 of 11 had a complete remis

121 of 34 treated patients); eight patients had stable disease at EoS, and some experienced complete or

122 With conventional imaging, 31 patients had stable disease at first restaging scans, and 15 of these

123 esponse, 6 had a partial response, and 3 had stable disease at last follow-up.

124 Thirty-one patients with stable disease at week 12 were randomly assigned.

125 Eight patients had stable disease at week 8, and 6 of these 8 patients had

126 h a disease control rate (partial response + stable disease) at 24 weeks of 84%.

127 fined as complete or partial response, or as stable disease beyond 16 weeks-of 34% in 215 treated pat

128 CI, 1% to 24%) and seven other patients had stable disease by RECIST criteria.

129 ts (85.7%) with nonenhancing glioma achieved stable disease compared with 14 of 31 (45.2%) with enhan

130 Responding patients and those with stable disease continued to be given daily chlorambucil

131 Chronic hepatitis C may follow a mild and stable disease course or progress rapidly to cirrhosis a

132 tients after HSCT were more likely to have a stable disease course when undergoing HSCT at an early s

133 receiving regular agalsidase-beta dose had a stable disease course, but dose reduction led to worseni

134 owed complete response, partial response, or stable disease (disease control) at 3 mo (95% confidence

135 lioma (LGG) often experience long periods of stable disease, emphasizing the importance of maintainin

136 mic signals can distinguish progressive from stable disease even 10 years before histopathological tr

137 3%) patients who achieve partial response or stable disease express high levels of AhR, whereas 12/16

138 ns by week 12, with no new lesions seen; (2) stable disease, followed by a slow, steady decline in to

139 n = 7, 4%), with 27 patients (17%) achieving stable disease for >/= 4 months.

140 artial response and eight patients (24%) had stable disease for >/= 6 months.

141 ieved a partial response; eight patients had stable disease for >/= six cycles, seven of whom had sar

142 , unconfirmed, or immune-related response or stable disease for >/=24 weeks) was observed in 65% of p

143 Of 17 evaluable patients, four had stable disease for 12 weeks to 14 months.

144 after a complete response for 38 months and stable disease for 16 months, respectively.

145 ts with MCL, although one patient maintained stable disease for 26 months.

146 Although some patients experienced stable disease for 3 months, none had tumor shrinkage, w

147 ancer treatment, withdrew consent, died, had stable disease for 6 weeks or longer, or had two or more

148 rtial response for more than 9 months, 7 had stable disease for 8 weeks to 29 months, and 8 progresse

149 defined as a complete or partial response or stable disease for at least 6 months); progression-free

150 esponse = 7 [13%]) and 10 (19%) patients had stable disease for at least 6 months, for a clinical ben

151 ed solid tumors, with 41% of patients having stable disease for at least 8 weeks.

152 Two (9%) of 23 patients had stable disease for more than 6 months, and seven patient

153 eved a partial response and seven maintained stable disease for more than 6 months.

154 Partial responders showed stable disease for the duration of the follow-up.

155 Five patients experienced stable disease for three to 24 cycles.

156 nd secondary graft failure, lethal GvHD, and stable, disease-free full donor engraftment using reduce

157 Eight patients experienced stable disease > 3 months, including a patient with meta

158 omplete response or partial response [PR] or stable disease >/= 16 weeks).

159 complete response plus partial response plus stable disease >/= 24 weeks) and progression-free surviv

160 rate (complete response + partial response + stable disease >/= 4 months), 43%.

161 rate (complete response + partial response + stable disease >/= 6 months) was 46%.

162 Stable disease >/= 8 weeks was observed in 42% of patien

163 ively; an additional 50% and 44% experienced stable disease >/= 8 weeks, respectively.

164 ently associated with a greater frequency of stable disease >/=6 months/partial/complete remission [2

165 Among the 107 patients, the rate of stable disease >=6 months and partial or complete respon

166 67; 95% CI, 0.50-0.90; P = 0.007) and higher stable disease >=6 months/partial/complete remission rat

167 responses (>/= 5 to >/= 8 months) and three stable diseases >/= 4 months (4 to >/= 8 months) were se

168 s (>/=15 months and >/= 11 months) and eight stable diseases >/= 4 months (median, 8 months [4 to 14.

169 hich was defined as CR, partial response, or stable disease (>/= 16 weeks) by RECIST 1.0 criteria.

170 esulting in partial remission in 2 patients, stable disease in 1 patient, and mixed response in the o

171 enhanced CT revealed partial remission in 5, stable disease in 13, and progressive disease in 7 patie

172 e in 15 (27%), minimal response in 11 (20%), stable disease in 15 (27%), and progressive disease in 1

173 prised a minor response in 2 patients (10%), stable disease in 16 patients (80%; median time to progr

174 MA PET/CT) revealed partial remission in 14, stable disease in 2, and progressive disease in 9 patien

175 verall response after 3 treatment cycles was stable disease in 3 patients.

176 in five patients (T, n = 3; TC, n = 2), and stable disease in 38 patients (T, n = 27; TC, n= 11), wi

177 Objective response was obtained in 16% and stable disease in 50%.

178 4%), increase in 9.1% (control = 37.5%), and stable disease in 54.5% (control = 43.7%).

179 ission in 3, a partial remission in 12 and a stable disease in 6 patients.

180 s was complete response (CR) in 2 (9.5%) and stable disease in 7 (33.3%), yielding a disease control

181 ctive response rate at 12 weeks was 5%, with stable disease in 75% of patients.

182 disease in 10% (1/10 patients) at 3 mo, and stable disease in 8 of 10 patients and progressive disea

183 The best response was stable disease in 90% (9/10 patients) and progressive di

184 partial response (PR) in two patients (12%), stable disease in nine patients (56%), and progressive d

185 trol rates (complete or partial remission or stable disease in patients with formerly progressive dis

186 a partial response and 12 vs 14 patients had stable disease in the experimental arm vs mFOLFOX arm.

187 neuroendocrine features, one mixed response (stable disease) in a patient with sarcoma, and one nearl

188 ever, 17 (33%) showed durable (>/= 4 months) stable disease, including seven (47%) of 15 evaluable pa

189 (57%) of 37 response-evaluable patients had stable disease, including those with DLBCL, Hodgkin's ly

190 e disease (k=0.94, percent agreement=97.1%), stable disease (k=0.90, percent agreement=95%), partial

191 nine additional patients (27%) demonstrated stable disease lasting > 24 weeks.

192 higher rate of clinical benefit, defined as stable disease lasting >=6 months or an objective respon

193 Of 7 patients with MM, 4 had stable disease lasting 2-17 months.

194 response and an additional 10 patients with stable disease longer than 4 months were observed among

195 reduction in tumor volume) in five dogs and stable disease (<50% change in tumor volume) in four dog

196 30 (26%) of 117 patients had stable disease (median duration 6.0 months, 95% CI 4.7-1

197 edian response duration, 5.3 months); 16 had stable disease (median response duration, 5.3 months).

198 When stratified by responders vs stable disease/minimal response vs progressive disease/N

199 sponse (n = 0), partial response (n = 9), or stable disease (n = 11) was achieved in 20 of 23 (87.0%;

200 = 234) OS HR, 0.81; 95% CI, 0.59 to 1.11 and stable disease (n = 285) OS HR, 0.76; 95% CI, 0.57 to 1.

201 ponses included partial response (n = 4) and stable disease (n = 57).

202 sponse (n = 0), partial response (n = 8), or stable disease (n = 6) was achieved in 14 of 24 (58.3%;

203 pulmonary fibrosis (n=32) than in those with stable disease (n=23).

204 e response, n = 1; partial response, n = 11; stable disease, n = 17; and progressive disease, n = 8.

205 , n = 5) and 11 patients were nonresponders (stable disease, n = 9; progressive disease, n = 2).

206 l resolution of symptoms attributed to ECD), stable disease (no change in symptoms attributed to ECD)

207 n of proven or suspected lesion due to ECD), stable disease (no significant change in proven or suspe

208 Prolonged stable disease of at least 4 months was observed in four

209 astatic urothelial cancer achieving at least stable disease on first-line platinum-based chemotherapy

210 f 13 patients evaluable after cross-over had stable disease on sunitinib (6 to 27 weeks).

211 ho were younger than 71 years of age and had stable disease or a marginal, partial, or complete respo

212 Patients in both groups with stable disease or a minor response after 16 weeks were e

213 151 patients, 99 (66%) demonstrated at least stable disease or a partial response, indicating that so

214 Sputum from asthmatic patients with stable disease or acute exacerbations was further studie

215 Patients with stable disease or better after four cycles could continu

216 patients who discontinued pembrolizumab with stable disease or better after receiving at least 24 mon

217 Of 15 evaluable patients, 11 (73%) with stable disease or better at day 45 postinfusion were def

218 Patients achieving stable disease or better could continue ADI-PEG 20 monot

219 ibrutinib 560 mg once daily, and those with stable disease or better could enter a long-term extensi

220 st, two induction regimens; and had achieved stable disease or better in the first 100 days after ASC

221 th indolent B-cell non-Hodgkin lymphoma with stable disease or better lasting at least 6 months after

222 by tafasitamab monotherapy (in patients with stable disease or better) until disease progression.

223 15% achieved partial response or better (76% stable disease or better).

224 All patients achieved stable disease or better, and had decreased tumor volume

225 nical benefit that extended to patients with stable disease or better.

226 al infusions every 4 weeks for patients with stable disease or better.

227 f skin rashes were observed in patients with stable disease or complete remission at 4 wk or longer.

228 isits of SLE patients relative to those with stable disease or healthy controls.

229 e randomisation and received confirmation of stable disease or objective response.

230 Ten patients were enrolled; 8 achieved stable disease or objective responses, whereas 2 had dis

231 Patients with stable disease or progressive disease (PD) after no more

232 med recurrence in 26 patients whereas 32 had stable disease or remained disease-free.

233 es pemetrexed continuation for patients with stable disease or response to first-line pemetrexed-cont

234 ng progression compared with patients having stable disease or response.

235 In patients who had OR, stable disease, or PD, the median OS was 55-57, 56-74, a

236 In patients who had OR, stable disease, or PD, the median PFS was 26-30, 27-34,

237 response, partial response, minor response, stable disease, or progressive disease.

238 re to weekly CG, while WT models showed only stable disease over treatment.

239 kly CG, whereas wild-type models showed only stable disease over treatment.

240 ical benefit rate (fraction of patients with stable disease, partial response, or complete response)

241 Those with stable disease per RECIST at 12 weeks were randomly assi

242 disease duration and prolonged survival; the stable disease phase was extended by 88% using mutant Cu

243 hese alleles recapitulates the stochastic bi-stable disease phenotype.

244 Health states included stable disease, progressing disease, hospice, and death.

245 l arms (CAs) included overall response rate, stable disease, progression-free survival (PFS), and ove

246 se categories: complete or partial response, stable disease, progressive disease, and HPD (P = 0.001)

247 ients (33.3%) had a best overall response of stable disease (range, 1.2 to 6.7 months), six of whom h

248 e., complete response, partial response, and stable disease) ranged from 29% to 90% for (90)Y radioem

249 Response and stable disease rates were 0% and 58% for monotherapy ver

250 the nasopharynx and neck, and patients with stable disease received 71.2 Gy.

251 nses (>/= 18 months, >/= 7 months) and seven stable disease responses >/= 3 months (median, 9 months;

252 She is alive, with a stable disease restricted to the stomach, at 12 months f

253 y RECIST: partial response (PR) 21% (17/82), stable disease (SD) 40%, and progression (PD) 39%.

254 Patients achieving at least stable disease (SD) continued bevacizumab 15 mg/kg every

255 ders fulfilled one criterion, and those with stable disease (SD) fulfilled neither.

256 Best response was stable disease (SD) in 10 (23%) patients receiving inter

257 Fourteen patients (38%) had stable disease (SD) that lasted 1.5 to 21 months.

258 te response (CR), partial response (PR), and stable disease (SD) were 47/99 (47%), 39/99 (39%), and 1

259 lete/partial response (CR/PR), 17 cases with stable disease (SD), 5 patients with progressive disease

260 mplete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD).

261 responses (>/=300 mg/d) and 15 patients with stable disease (SD), with most responses lasting longer

262 patients with partial response (PR) or with stable disease (SD).

263 jective responses and 11 patients (28%) with stable disease (SD); the median progression-free surviva

264 There were 35 patients with stable disease (SD, 70%) and a 64% clinical benefit rate

265 complete or partial response [PR] as well as stable disease [SD] >/= 16 weeks).

266 t rate (CBR = complete + partial responses + stable disease [SD] >/= 24 weeks) and safety and pharmac

267 mplete response, 49%; partial response, 38%; stable disease [SD] or local disease progression [DP], 1

268 ete response [CR] or partial response [PR] v stable disease [SD] v progressive disease [PD]), disease

269 sses reflected by CSF biomarkers are robust, stable, disease specific, or even disease stage specific

270 Patients who achieved at least stable disease subsequently received 24 cycles of lenali

271 ficantly higher (P = 0.022) in patients with stable disease than in patients with progressive disease

272 who experienced complete remissions, PRs, or stable disease, the persisting CTLs acquired phenotypic

273 Thirty-five patients (47%) had stable disease: the change in their PSA level ranged fro

274 16 (36%) patients had stable disease; the remaining four (9%) had progressive

275 of SSc-ILD is variable, ranging from minor, stable disease to a progressive course, whereas all pati

276 enance (n = 48), five patients improved from stable disease to partial response, and one patient impr

277 during the first two vaccine courses; 19 had stable disease, two had partial responses, one had a min

278 rmed partial response, 24 patients (75%) had stable disease, two patients (6.3%) discontinued treatme

279 us, smoking history, and induction response (stable disease v partial response) subgroups.

280 umab and 0.43 (0.29-0.65) for docetaxel; for stable disease versus progressive disease, hazard ratios

281 IIA vs IIIB), response to chemoradiotherapy (stable disease vs objective response), delivery of chemo

282 t of complete response, partial response, or stable disease was 16 of 41 patients (39.0%, 95% CI 24.2

283 Stable disease was achieved in 23 patients.

284 comparator was 0% versus 4% (P = .925), and stable disease was achieved in 35% versus 17% of patient

285 3 patients overall (95% CI, 28.2% to 54.8%); stable disease was also observed in 22 of 53.

286 Stable disease was detected in 19 patients (67.8%) by on

287 Stable disease was maintained in the metronomic groups f

288 In 49% of tumors (19 of 39), stable disease was noted.

289 Stable disease was observed in 37.5% (90% CI, 25.8% to 5

290 ed average disease control rate (CR, PR, and stable disease) was 86% (95% confidence interval, 78%-92

291 complete response plus partial response plus stable disease) was 94% according to the response evalua

292 ion (complete, partial, or minor response or stable disease) was achieved in 47 patients (87.0%).

293 d by ORR, although minor tumor responses and stable disease were observed in some patients.

294 Those achieving response or stable disease were randomly assigned at a ratio of 1:1

295 ion, aged 70 years or younger, with at least stable disease, were randomly assigned (1:1) to treatmen

296 ed on ACH (-0.19 +/- 0.49 mm) yet relatively stable disease when based on PD (0.11 +/- 0.42 mm) and C

297 orter PFS and OS than patients with an OR or stable disease with all 4 scoring systems.

298 ive responses in patients achieving at least stable disease with first-line platinum-based chemothera

299 sarcomas who achieved objective response or stable disease with prior chemotherapy were randomly ass

300 progression of 23 weeks and 24 patients with stable disease, with the longest duration of 72 weeks an